Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
COVID-19: early-phase trial registry
68 of 299 indexed COVID-19 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #30 of 28,707 conditions by registered trial count.
299 US clinical trials · 68 currently recruiting · #30 of 28,707 conditions by registered trial count
COVID-19: 299 US clinical trials tracked, 68 recruiting.
COVID-19 is the subject of 299 registered US clinical trials on ClinicalTrials.gov, 68 of them currently open to new participants. 42 are in Phase 3-4 (later-stage) and 83 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 16 of these trials.
Enrollment posture brief
Registry condition covid-19
OPEN 68 | RECR 23% | LATE 42 | EARLY 83 | RANK #30 | SPON 16
Volume-matched condition peers
Nearest open-share peer: Hypogonadism (23% recruiting · 22 trials)
COVID-19 lists 68 open slots (23% of 299 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for COVID-19 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
COVID-19 is recruiting below its size-band peers.
68 of 299 indexed trials (22.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of COVID-19 trials is spread across many organizations.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 16 of 299 trials (5.4%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical COVID-19 enrolment sits around 245 participants.
Median target enrolment is 245 among the 299 trials that report a genuine target (sentinel values excluded). 96 of those (32.1%) plan for fewer than 100 participants.
-
COVID-19 splits between interventional and observational designs.
196 interventional and 103 observational studies make up this index (65.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
299 total, page 6 of 6
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19
Intermountain Health Care
NCT04329832
Cardiovascular Effects of COVID-19
NYU Langone Health
NCT04365699
WGS Analysis of COVID-19 Positive Patients
Vanda Pharmaceuticals
NCT04353401
Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)
Washington University School of Medicine
NCT05947643
Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy
The University of Texas Medical Branch, Galveston
NCT03554265
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
Apellis Pharmaceuticals
NCT04402060
Camostat Mesylate in COVID-19 Outpatients
Yale University
NCT04353284
Incidence and Predictors of Acute and Chronic Complications in Patients With Diabetes and Severe COVID-19
University of Michigan
NCT05200819
Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19
National Cancer Institute (NCI)
NCT05044780
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
BeiGene
NCT04382586
RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19
University of California, San Diego
NCT04939415
Do EEG and Neurocognitive Assessments Correlate With COVID Brainfog Symptoms?
Texas Tech University Health Sciences Center, El Paso
NCT05303116
COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications
James L. Kirkland, MD, PhD
NCT04771611
RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19
Gordon Saxe
NCT04667247
Baseline Vitamin D Deficiency and COVID-19 Disease Severity
Parkview Medical Center
NCT04628000
Nebulized Heparin for the Treatment of COVID-19
Frederick Health
NCT04723563
Breath Analysis Based Disease Biomarkers
Mayo Clinic
NCT04341012
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
Cellenkos
NCT04468971
Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic
University of Virginia
NCT04368260
Blood Volume Assessment in COVID-19 and Bacterial Sepsis
NYU Langone Health
NCT04517695
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
Vaxart
NCT04563702
Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19
University of Kentucky
NCT04412330
Home Usability Study of the SARS-CoV-2 (COVID-19) Test
Exact Sciences Corporation
NCT04395391
Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection
Cellular Sciences
NCT04824365
Frontline Clinician Psilocybin Study
University of Washington
NCT05163496
Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection
Thomas Jefferson University
NCT04765449
DCI COVID-19 Surveillance Project
Temple University
NCT04780698
Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients
Cytokind
NCT04818970
Cognitive Assessment in COVID-19 Positive Patients Using the DANA App
Johns Hopkins University
NCT05143333
Compass Course: COVID-19
Allina Health System
NCT05295238
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
Eli Lilly and Company
NCT04411628
CPAP Efficacy in Post-COVID-19 Patients With Sleep Apnea
Venkatesh Krishnamurthy
NCT06052514
Prognostic Models for COVID-19 Care
Tufts Medical Center
NCT04689711
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease
Novartis Pharmaceuticals
NCT04358081
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19
Senhwa Biosciences
NCT04663737
Core Warming in COVID-19 Patients Undergoing Mechanical Ventilation
Sharp HealthCare
NCT04494867
A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)
University of Kansas Medical Center
NCT04481685
Electrical Stimulation for Critically Ill Covid-19 Patients
Baylor College of Medicine
NCT04685213
Zofin to Treat COVID-19 Long Haulers
ZEO ScientifiX
NCT05228899
Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
George Washington University
NCT05063812
A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.
Pfizer
NCT06586216
COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05518487
COVID-19 Study of Safety and Tolerability of Alvelestat
University of Alabama at Birmingham
NCT04539795
Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate
University of Pennsylvania
NCT05080192
Prognostication of Recovery in Early Disorders of Consciousness After COVID-19
Massachusetts General Hospital
NCT04476589
Famotidine Outpatient COVID-19 Treatment Study
Northwell Health
NCT04389567
Implementation of COVID-19 Testing Strategies in Community Health Centers
Massachusetts General Hospital
NCT04802187
Contrast Enhanced Ultrasound in COVID-19
Children's Hospital of Philadelphia
NCT04640038
Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19
Memorial Sloan Kettering Cancer Center
NCT04824443
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 28 |
| Phase 2 | 55 |
| Phase 3 | 31 |
| Phase 4 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on COVID-19 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on COVID-19 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this COVID-19 page
299 registered trials, 68 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 68 COVID-19 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most COVID-19 trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This COVID-19 condition card totals 299 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.